Eris Lifesciences Q3 Results Review - In-Line; MR Productivity On An Uptrend: Motilal Oswal

Motilal Oswal Report

Eris Lifesciences Ltd. reported an in-line Q3 FY24 performance. Core therapies (63% of revenue) outperformed the industry by 300 basis points YoY for the quarter. Eris Lifesciences has announced that it is venturing into injectable products by acquiring Swiss Parenterals Ltd.

Further, this acquisition marks the beginning of the exports business for Eris. Considering Swiss Parenterals’ FY24 sales of Rs 3.4 billion, the deal is valued at enterprise value/sales of 3.7 times. Moreover, considering 30- 35% margin, the EV/Ebitda stands at 10.6 times-12.4 times.

We raise our earnings estimates by 3%/2% for FY25/FY26, factoring in:

1. The addition of business from Swiss Parenterals, and

2. Improving gross margin in the Biocon portfolio.

We value Eris at 23 times 12 months forward earnings to arrive at our target price of Rs 950.

Reiterate 'Neutral'.

Click on the attachment to read the full report:

DISCLAIMER

This report is authored by an external party. NDTV Profit does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of NDTV Profit.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.